Clinical Scorecard: A Prospective, Blinded Investigation of Thyrotropin Receptor Antibodies in Autoimmune Thyroid Disorders Conducted in the United States
Thyrotropin receptor antibodies (TSH-R-Ab) stimulate or block TSH receptor activity affecting thyroid hormone production
Target Population
Patients with various thyroid diseases including Graves’ disease, autoimmune thyroiditis, toxic nodular goiter, euthyroid nodules, thyroid cancer, and healthy controls
Care Setting
Endocrinology outpatient clinics in the United States
Key Highlights
TSH-R-Ab bioassays measuring thyroid-stimulating immunoglobulin (TSI) are more sensitive than automated binding assays for detecting stimulating antibodies in Graves’ disease.
Binding assays cannot differentiate between stimulating and blocking TSH-R antibodies, whereas bioassays can determine antibody functionality.
Measurement of TSH-R-Ab is recommended by American and European Thyroid Associations for diagnosis and management of autoimmune hyperthyroidism, but guidelines do not specify assay type.
Guideline-Based Recommendations
Diagnosis
Include measurement of TSH-R-Ab in the diagnostic evaluation of autoimmune hyperthyroidism.
Management
Use TSH-R-Ab status to guide decisions on discontinuing antithyroid medications in Graves’ disease due to relapse risk associated with elevated antibody levels.
Monitoring & Follow-up
Monitor TSH-R-Ab levels to assess disease activity and treatment response.
Risks
Relapse of Graves’ disease is higher in patients with elevated TSH-R-Ab levels.
Patient & Prescribing Data
Patients with Graves’ disease and other autoimmune thyroid disorders
TSH-R-Ab bioassay positivity correlates better with disease activity and may improve clinical decision-making compared to binding assays.
Clinical Best Practices
Preferentially use cell-based bioassays to measure functional TSH-R-Ab (TSI and TBI) for accurate assessment of antibody activity.
Recognize that binding assays have lower sensitivity and cannot distinguish stimulating from blocking antibodies.
Incorporate TSH-R-Ab testing into routine evaluation and management of autoimmune thyroid disease to optimize treatment strategies.
Most surgeons reported using intraoperative parathyroid hormone monitoring, but approaches to imaging and intraoperative criteria varied, particularly in secondary and tertiary disease
